Tumor Markers in Neuroendocrine Cancer
Chromogranin A (CgA) is the primary tumor marker recommended for neuroendocrine tumors, with 24-hour urine 5-HIAA specifically indicated for metastatic small intestinal NETs, particularly those with carcinoid syndrome. 1
Primary Tumor Markers
Chromogranin A (CgA)
- CgA serves as the best general tumor marker for most NETs, expressed in 80-90% of patients with gastroenteropancreatic NETs and should be used for diagnosis, follow-up, and treatment monitoring 2
- CgA levels elevated twice the normal limit or higher are associated with shorter survival in metastatic NETs (HR 2.8; 95% CI 1.9-4.0; P<0.001) 1
- Critical caveat: CgA can be falsely elevated in renal or hepatic insufficiency and is commonly elevated with concurrent proton pump inhibitor use 1
- Important limitation: Increasing CgA levels in asymptomatic patients with stable imaging should not automatically trigger new therapy 1
- CgA has 68% sensitivity and 86% specificity in GEP tumors, with highest sensitivity in metastatic and syndromic patients 3
5-Hydroxyindoleacetic Acid (5-HIAA)
- 24-hour urine 5-HIAA is specifically recommended for metastatic small intestinal NETs and monitoring carcinoid tumors 1
- Decreasing 5-HIAA levels indicate treatment response, while increasing levels suggest treatment failure 1
- Critical dietary restrictions required 48 hours before collection: avoid avocados, bananas, cantaloupe, eggplant, pineapples, plums, tomatoes, hickory nuts/pecans, plantains, kiwi, dates, grapefruit, honeydew, walnuts, coffee, alcohol, and smoking 1
- Medications that interfere: acetaminophen, ephedrine, diazepam, nicotine, guaifenesin, and phenobarbital can increase 5-HIAA 1
- Normal 5-HIAA does not exclude NET in symptomatic patients 1
Functional Tumor-Specific Markers
Pancreatic NETs
- Gastrin: for Zollinger-Ellison syndrome; secretin stimulation test can confirm diagnosis 1, 4
- Insulin/Proinsulin: for insulinoma syndrome; 72-hour fast is the diagnostic test 1, 4
- Glucagon: for glucagonoma syndrome 1, 4
- Vasoactive intestinal peptide (VIP): for WDHA/Verner-Morrison syndrome 1, 4
- Pancreatic polypeptide (PP): often elevated in nonfunctioning pancreatic NETs 1
Rectal NETs
- Typically nonfunctioning but may secrete PP, somatostatin, and PYY 1
Alternative and Supplementary Markers
Neuron-Specific Enolase (NSE)
- NSE is the preferred marker for poorly differentiated neuroendocrine carcinomas (G3 tumors) where CgA is often normal 1, 5
- NSE shows close to 90% sensitivity in neuroblastomas across all clinical stages 3
- NSE is associated with survival in poorly differentiated NEC (P=0.003) 5
Cytokeratin Fragments (CKfr)
- CKfr (CK8, CK18, CK19) are associated with survival in both well-differentiated NETs (P<0.0001) and poorly differentiated NEC (P<0.0001) 5
- Combination of CKfr with other markers provides superior diagnostic and prognostic information 5
ProGRP (Progastrin-Releasing Peptide)
- ProGRP shows 73% sensitivity at 95% specificity in small cell neuroendocrine carcinoma 5
- Recommended for SCNEC in combination with CKfr 5
Recommended Marker Strategy by Tumor Type
Well-Differentiated NETs (G1/G2)
- Primary markers: CgA and CKfr 5
- Add 5-HIAA for small intestinal NETs 1
- Add specific hormones based on clinical syndrome 1, 4
Poorly Differentiated NEC (G3)
- For large cell NEC: CgA and CKfr 5
- For small cell NEC: ProGRP and CKfr 5
- NSE as supplementary marker 5
Carcinoid Syndrome
- Both CgA and 24-hour urine 5-HIAA are essential, as carcinoid syndrome results from hormone release from liver metastases, not primary tumors 1
Common Pitfalls to Avoid
- Do not rely solely on CgA in patients on proton pump inhibitors without considering false elevation 1
- Do not initiate new therapy based on rising CgA alone if imaging shows stable disease 1
- Do not forget dietary restrictions before 5-HIAA collection, as this causes false results 1
- Do not use CgA as primary marker in poorly differentiated G3 tumors; use NSE instead 1, 5
- Do not assume normal 5-HIAA excludes NET in symptomatic patients 1